Operaciones Alimera Sciences, Inc. - ALIM CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.27 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.030779% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.013666% | ||||||||
Horario tarifa nocturna | 22:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 2.39 |
Abrir* | 2.42 |
Cambio de 1 año* | -46.93% |
Rango del día* | 2.42 - 2.42 |
Rango de 52 semanas | 2.03-7.92 |
Volumen medio (10 días) | 15.54K |
Volumen medio (3 meses) | 325.95K |
Capitalización de mercado | 17.52M |
Ratio P/E | -100.00K |
Acciones en circulación | 7.01M |
Ingresos | 54.06M |
EPS | -2.64 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.39 |
Próxima fecha de resultados | Feb 22, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 2.42 | 0.00 | 0.00% | 2.42 | 2.42 | 2.42 |
Feb 7, 2023 | 2.39 | -0.17 | -6.64% | 2.56 | 2.56 | 2.36 |
Feb 6, 2023 | 2.59 | -0.12 | -4.43% | 2.71 | 2.77 | 2.56 |
Feb 3, 2023 | 2.73 | -0.02 | -0.73% | 2.75 | 2.85 | 2.63 |
Feb 2, 2023 | 2.70 | -0.11 | -3.91% | 2.81 | 2.88 | 2.70 |
Feb 1, 2023 | 2.77 | 0.10 | 3.75% | 2.67 | 2.77 | 2.66 |
Jan 31, 2023 | 2.60 | 0.09 | 3.59% | 2.51 | 2.67 | 2.51 |
Jan 30, 2023 | 2.56 | 0.15 | 6.22% | 2.41 | 2.59 | 2.37 |
Jan 27, 2023 | 2.51 | 0.07 | 2.87% | 2.44 | 2.51 | 2.42 |
Jan 26, 2023 | 2.51 | -0.04 | -1.57% | 2.55 | 2.60 | 2.45 |
Jan 25, 2023 | 2.50 | -0.01 | -0.40% | 2.51 | 2.52 | 2.49 |
Jan 24, 2023 | 2.42 | 0.00 | 0.00% | 2.42 | 2.42 | 2.41 |
Jan 23, 2023 | 2.43 | -0.11 | -4.33% | 2.54 | 2.57 | 2.38 |
Jan 20, 2023 | 2.60 | -0.20 | -7.14% | 2.80 | 2.80 | 2.60 |
Jan 19, 2023 | 2.64 | -0.09 | -3.30% | 2.73 | 2.73 | 2.62 |
Jan 18, 2023 | 2.73 | -0.19 | -6.51% | 2.92 | 2.94 | 2.71 |
Jan 17, 2023 | 2.91 | -0.03 | -1.02% | 2.94 | 2.99 | 2.90 |
Jan 13, 2023 | 3.00 | -0.03 | -0.99% | 3.03 | 3.06 | 3.00 |
Jan 12, 2023 | 2.80 | 0.00 | 0.00% | 2.80 | 2.99 | 2.65 |
Jan 11, 2023 | 2.42 | -0.13 | -5.10% | 2.55 | 2.55 | 2.41 |
Alimera Sciences, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos totales | 34.333 | 35.912 | 46.599 | 53.943 | 50.82 | 59.029 |
Ingresos | 34.333 | 35.912 | 46.599 | 53.943 | 50.82 | 59.029 |
Coste de los ingresos, total | 2.344 | 3.438 | 4.308 | 6.626 | 6.941 | 7.03 |
Beneficio bruto | 31.989 | 32.474 | 42.291 | 47.317 | 43.879 | 51.999 |
Gastos totales de explotación | 64.744 | 52.364 | 58.035 | 59.217 | 51.321 | 57.438 |
Gastos de venta/general/administración Gastos, total | 44.694 | 36.249 | 38.042 | 38.958 | 32.036 | 35.843 |
Investigación y desarrollo | 12.375 | 12.844 | 11.274 | 10.992 | 9.668 | 13.778 |
Depreciation / Amortization | 2.767 | 2.684 | 2.645 | 2.641 | 2.676 | 2.579 |
Gastos (ingresos) extraordinarios | 2.564 | 0 | 1.766 | 0 | -1.792 | |
Ingresos de explotación | -30.411 | -16.452 | -11.436 | -5.274 | -0.501 | 1.591 |
Ingresos por intereses (gastos), netos No operativos | -2.591 | -5.386 | -4.84 | -4.953 | -4.906 | -4.997 |
Ingresos netos antes de impuestos | -33.002 | -21.838 | -16.276 | -10.227 | -5.407 | -3.934 |
Ingresos netos después de impuestos | -33.174 | -22.001 | -16.382 | -10.443 | -5.339 | -4.372 |
Beneficio neto antes de partidas extra. Elementos | -33.174 | -22.001 | -16.382 | -10.443 | -5.339 | -4.372 |
Ingresos netos | -33.174 | -22.001 | -16.382 | -10.443 | -5.339 | -4.372 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -33.174 | -22.001 | 21.948 | -10.443 | -5.339 | -4.372 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -33.174 | -22.001 | 21.948 | -10.443 | -5.339 | -4.372 |
Beneficio neto diluido | -33.174 | -22.001 | 21.948 | -10.443 | -5.339 | -4.372 |
Promedio ponderado de acciones diluidas | 52.8016 | 66.9937 | 5.91587 | 4.7702 | 5.11766 | 6.59524 |
BPA diluido sin partidas extraordinarias | -0.62828 | -0.3284 | 3.71002 | -2.18921 | -1.04325 | -0.6629 |
BPA normalizado diluido | -0.59671 | -0.3284 | 3.90406 | -2.18921 | -1.04325 | -0.83951 |
Other Operating Expenses, Total | -2.851 | |||||
Total de partidas extraordinarias | 0 | 0 | 0 | |||
Total Adjustments to Net Income | 38.33 | 0 | ||||
Otros, netos | -0.528 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Ingresos totales | 11.214 | 21.703 | 12.153 | 13.959 | 11.898 |
Ingresos | 11.214 | 21.703 | 12.153 | 13.959 | 11.898 |
Coste de los ingresos, total | 1.562 | 1.813 | 1.689 | 1.966 | 1.68 |
Beneficio bruto | 9.652 | 19.89 | 10.464 | 11.993 | 10.218 |
Gastos totales de explotación | 13.644 | 12.908 | 14.175 | 16.711 | 16.045 |
Gastos de venta/general/administración Gastos, total | 8.231 | 8.687 | 8.559 | 10.366 | 10.093 |
Investigación y desarrollo | 3.213 | 3.567 | 3.278 | 3.72 | 3.583 |
Depreciation / Amortization | 0.638 | 0.633 | 0.649 | 0.659 | 0.689 |
Ingresos de explotación | -2.43 | 8.795 | -2.022 | -2.752 | -4.147 |
Ingresos por intereses (gastos), netos No operativos | -1.218 | -1.291 | -1.218 | -1.27 | -1.256 |
Ingresos netos antes de impuestos | -3.648 | 8.205 | -4.352 | -4.139 | -5.955 |
Ingresos netos después de impuestos | -3.648 | 7.565 | -4.183 | -4.106 | -5.955 |
Beneficio neto antes de partidas extra. Elementos | -3.648 | 7.565 | -4.183 | -4.106 | -5.955 |
Ingresos netos | -3.648 | 7.565 | -4.183 | -4.106 | -5.955 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -3.648 | 7.565 | -4.183 | -4.106 | -5.955 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -3.648 | 7.565 | -4.183 | -4.106 | -5.955 |
Beneficio neto diluido | -3.648 | 7.565 | -4.183 | -4.106 | -5.955 |
Promedio ponderado de acciones diluidas | 5.75542 | 7.36315 | 6.92417 | 6.93809 | 6.99074 |
BPA diluido sin partidas extraordinarias | -0.63384 | 1.02741 | -0.60412 | -0.59181 | -0.85184 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -0.63384 | 0.80302 | -0.60412 | -0.59181 | -0.85184 |
Gastos (ingresos) extraordinarios | -1.792 | 0 | 0 | ||
Otros, netos | 0.701 | -1.112 | -0.117 | -0.552 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Activo Corriente | 47.402 | 39.322 | 34.848 | 32.745 | 34.906 | 42.16 |
Efectivo e inversiones a corto plazo | 30.979 | 24.067 | 13.043 | 9.426 | 11.208 | 16.51 |
Efectivo y Equivalentes | 30.979 | 24.067 | 13.043 | 9.426 | 11.208 | 16.51 |
Total deudores, neto | 13.839 | 11.435 | 17.259 | 19.331 | 17.2 | 19.128 |
Accounts Receivable - Trade, Net | 13.839 | 11.435 | 17.259 | 19.331 | 17.2 | 19.128 |
Total Inventory | 0.446 | 1.508 | 2.405 | 1.39 | 2.746 | 2.679 |
Prepaid Expenses | 2.107 | 2.278 | 2.109 | 2.565 | 3.718 | 3.809 |
Other Current Assets, Total | 0.031 | 0.034 | 0.032 | 0.033 | 0.034 | 0.034 |
Total Assets | 70.229 | 59.924 | 54.108 | 50.309 | 50.855 | 58.52 |
Property/Plant/Equipment, Total - Net | 1.787 | 1.41 | 1.355 | 2.047 | 2.358 | 4.493 |
Property/Plant/Equipment, Total - Gross | 4.421 | 4.611 | 4.967 | 5.858 | 6.305 | 7.923 |
Accumulated Depreciation, Total | -2.634 | -3.201 | -3.612 | -3.881 | -3.947 | -3.43 |
Intangibles, Net | 20.604 | 18.664 | 16.723 | 14.783 | 12.838 | 10.897 |
Other Long Term Assets, Total | 0.436 | 0.528 | 1.182 | 0.734 | 0.753 | 0.137 |
Total Current Liabilities | 9.123 | 9.671 | 10.234 | 12.048 | 12.348 | 12.592 |
Accounts Payable | 4.986 | 5.905 | 6.355 | 7.077 | 7.461 | 8.706 |
Accrued Expenses | 3.758 | 3.582 | 3.643 | 4.716 | 3.197 | 3.617 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.191 | 0.184 | 0.236 | 0.255 | 1.69 | 0.269 |
Other Current Liabilities, Total | 0.188 | 0 | ||||
Total Liabilities | 44.643 | 45.005 | 51.386 | 54.754 | 58.833 | 61.125 |
Total Long Term Debt | 33.358 | 34.568 | 38.178 | 38.752 | 42.922 | 43.08 |
Long Term Debt | 33.084 | 34.365 | 37.873 | 38.658 | 42.408 | 43.08 |
Capital Lease Obligations | 0.274 | 0.203 | 0.305 | 0.094 | 0.514 | |
Other Liabilities, Total | 2.162 | 0.766 | 2.974 | 3.954 | 3.563 | 5.453 |
Total Equity | 25.586 | 14.919 | 2.722 | -4.445 | -7.978 | -2.605 |
Preferred Stock - Non Redeemable, Net | 68.795 | 68.795 | 30.344 | 30.344 | 19.227 | 19.227 |
Common Stock | 0.649 | 0.691 | 0.701 | 0.05 | 0.057 | 0.069 |
Additional Paid-In Capital | 330.781 | 341.622 | 346.108 | 350.117 | 365.83 | 377.229 |
Retained Earnings (Accumulated Deficit) | -373.367 | -395.368 | -373.42 | -383.863 | -392.539 | -397.281 |
Other Equity, Total | -1.272 | -0.821 | -1.011 | -1.093 | -0.553 | -1.849 |
Total Liabilities & Shareholders’ Equity | 70.229 | 59.924 | 54.108 | 50.309 | 50.855 | 58.52 |
Total Common Shares Outstanding | 4.32419 | 4.60976 | 4.67193 | 4.96595 | 5.71937 | 6.93515 |
Total Preferred Shares Outstanding | 0.60842 | 0.60842 | 0.61015 | 0.61015 | 0.6 | 0.6 |
Long Term Investments | 0.833 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 30.33 | 45.237 | 43.633 | 42.16 | 34.753 |
Efectivo e inversiones a corto plazo | 8.266 | 24.78 | 21.524 | 16.51 | 9.946 |
Efectivo y Equivalentes | 8.266 | 24.78 | 21.524 | 16.51 | 9.946 |
Total deudores, neto | 15.702 | 15.086 | 16.21 | 19.128 | 18.776 |
Accounts Receivable - Trade, Net | 15.702 | 15.086 | 16.21 | 19.128 | 18.776 |
Total Inventory | 2.591 | 2.307 | 2.301 | 2.679 | 2.452 |
Prepaid Expenses | 3.736 | 3.029 | 3.564 | 3.809 | 3.546 |
Other Current Assets, Total | 0.035 | 0.035 | 0.034 | 0.034 | 0.033 |
Total Assets | 45.587 | 62.102 | 60.065 | 58.52 | 49.931 |
Property/Plant/Equipment, Total - Net | 2.178 | 2.199 | 3.383 | 4.493 | 4.343 |
Intangibles, Net | 12.359 | 11.875 | 11.386 | 10.897 | 10.419 |
Other Long Term Assets, Total | 0.72 | 0.729 | 0.712 | 0.137 | 0.134 |
Total Current Liabilities | 11.209 | 10.308 | 11.399 | 12.592 | 17.006 |
Accounts Payable | 6.343 | 7.083 | 7.437 | 8.706 | 6.604 |
Accrued Expenses | 2.873 | 2.924 | 3.673 | 3.617 | 3.046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.993 | 0.301 | 0.289 | 0.269 | 7.356 |
Total Liabilities | 57.547 | 56.211 | 58.563 | 61.125 | 58.534 |
Total Long Term Debt | 42.803 | 42.595 | 42.838 | 43.08 | 36.245 |
Long Term Debt | 42.352 | 42.595 | 42.838 | 43.08 | 36.245 |
Capital Lease Obligations | 0.451 | ||||
Other Liabilities, Total | 3.535 | 3.308 | 4.326 | 5.453 | 5.283 |
Total Equity | -11.96 | 5.891 | 1.502 | -2.605 | -8.603 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 19.227 | 19.227 |
Common Stock | 0.058 | 0.069 | 0.069 | 0.069 | 0.07 |
Additional Paid-In Capital | 366.092 | 376.334 | 376.579 | 377.229 | 377.541 |
Retained Earnings (Accumulated Deficit) | -396.187 | -388.622 | -392.805 | -397.281 | -403.236 |
Other Equity, Total | -1.15 | -1.117 | -1.568 | -1.849 | -2.205 |
Total Liabilities & Shareholders’ Equity | 45.587 | 62.102 | 60.065 | 58.52 | 49.931 |
Total Common Shares Outstanding | 5.75349 | 6.92417 | 6.92717 | 6.93515 | 6.99265 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
Long Term Investments | 2.062 | 0.951 | 0.833 | 0.282 | |
Other Current Liabilities, Total | 0 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos netos/Línea de salida | -33.174 | -22.001 | -16.382 | -10.443 | -5.339 | -4.372 |
Efectivo de actividades de explotación | -25.099 | -12.874 | -11.553 | -4.152 | -2.193 | -3.224 |
Efectivo de actividades de explotación | 2.767 | 2.684 | 2.645 | 2.641 | 2.676 | 2.579 |
Deferred Taxes | -0.213 | -0.092 | -0.653 | 0.454 | 0.031 | 0.61 |
Partidas no monetarias | 6.008 | 6.238 | 7.084 | 3.377 | 1.829 | -0.692 |
Cash Taxes Paid | 0.193 | 0.074 | 0.239 | 0.239 | 0.11 | 0.112 |
Intereses pagados en efectivo | 3.958 | 4.117 | 3.571 | 4.419 | 4.556 | 4.302 |
Cambios en el capital circulante | -0.487 | 0.297 | -4.247 | -0.181 | -1.39 | -1.349 |
Efectivo de actividades de inversión | -0.186 | -0.238 | -0.175 | -0.174 | -0.62 | -0.621 |
Gastos de capital | -0.186 | -0.238 | -0.175 | -0.174 | -0.62 | -0.621 |
Efectivo procedente de actividades de financiación | 25.424 | 5.723 | 0.95 | 0.869 | 3.882 | 9.823 |
Elementos de flujo de caja de financiación | -1.063 | 0.003 | -3.808 | -2.227 | -0.019 | 0 |
Emisión (retiro) de acciones, neto | 26.714 | 5.902 | 0.085 | 0.902 | 0.049 | 10.044 |
Emisión (amortización) de deuda, neta | -0.227 | -0.182 | 4.673 | 2.194 | 3.852 | -0.221 |
Efectos del cambio de divisas | -0.235 | 0.477 | -0.248 | -0.159 | 0.714 | -0.676 |
Variación neta de la tesorería | -0.096 | -6.912 | -11.026 | -3.616 | 1.783 | 5.302 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.648 | 3.917 | -0.266 | -4.372 | -5.955 |
Cash From Operating Activities | -2.501 | 4.191 | 1.459 | -3.224 | -6.213 |
Cash From Operating Activities | 0.638 | 1.271 | 1.92 | 2.579 | 0.689 |
Non-Cash Items | 0.377 | -2.653 | -1.197 | -0.692 | 1.027 |
Cash Taxes Paid | 0.004 | 0.023 | 0.047 | 0.112 | 0.018 |
Cash Interest Paid | 1.061 | 2.145 | 3.23 | 4.302 | 1.061 |
Changes in Working Capital | 0.132 | 1.656 | 1.002 | -1.349 | -1.974 |
Cash From Investing Activities | -0.084 | -0.19 | -0.5 | -0.621 | -0.149 |
Capital Expenditures | -0.084 | -0.19 | -0.5 | -0.621 | -0.149 |
Cash From Financing Activities | -0.057 | 9.891 | 9.842 | 9.823 | -0.062 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Debt, Net | -0.057 | -0.112 | -0.16 | -0.221 | -0.062 |
Foreign Exchange Effects | -0.299 | -0.319 | -0.485 | -0.676 | -0.141 |
Net Change in Cash | -2.941 | 13.573 | 10.316 | 5.302 | -6.565 |
Issuance (Retirement) of Stock, Net | 10.003 | 10.002 | 10.044 | ||
Deferred Taxes | 0.61 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Ocumension Therapeutics | Corporation | 16.3366 | 1144945 | 0 | 2022-05-17 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 9.4761 | 664132 | 106222 | 2022-09-30 | MED |
Caligan Partners, LP | Hedge Fund | 5.8718 | 411527 | 411527 | 2022-05-25 | LOW |
HOOPP Investment Management | Pension Fund | 3.5671 | 250000 | 0 | 2022-09-30 | HIGH |
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 3.2475 | 227602 | 40601 | 2022-09-30 | MED |
Palo Alto Investors LP | Hedge Fund | 2.8668 | 200919 | 0 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1198 | 148566 | -793 | 2022-09-30 | LOW |
Eiswirth (Richard S Jr) | Individual Investor | 1.9408 | 136018 | 500 | 2022-10-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.608 | 112694 | -14999 | 2022-09-30 | HIGH |
Holland (David R) | Individual Investor | 0.5762 | 40380 | 500 | 2022-10-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5468 | 38320 | 12002 | 2022-09-30 | LOW |
Jones (John Philip) | Individual Investor | 0.4592 | 32186 | 372 | 2022-10-31 | LOW |
Ashman Philip | Individual Investor | 0.4325 | 30315 | -2889 | 2023-02-03 | |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2788 | 19542 | 0 | 2022-09-30 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2611 | 18300 | 0 | 2022-09-30 | LOW |
Perritt Capital Management, Inc. | Investment Advisor | 0.2568 | 18000 | -9400 | 2022-09-30 | LOW |
Skibsted (Russell L) | Individual Investor | 0.2497 | 17500 | 17500 | 2023-01-09 | |
Largent (James R.) | Individual Investor | 0.1855 | 13000 | 0 | 2022-05-17 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1745 | 12232 | -12369 | 2022-09-30 | LOW |
Snisarenko (John) | Individual Investor | 0.1427 | 10000 | 0 | 2022-05-17 |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com GroupTraders
Clientes activos mensualmente
Volumen mensual de inversión
Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
Sobre Alimera Sciences Inc
Alimera Sciences, Inc. es una empresa farmacéutica. La empresa se dedica a la comercialización y el desarrollo de productos farmacéuticos oftálmicos de prescripción. Se centra en las enfermedades que afectan al fondo del ojo o a la retina. El producto comercial de la empresa, ILUVIEN, es un implante intravítreo que trata a los pacientes mediante la administración de una microdosis continua del corticosteroide no patentado acetónido de fluocinolona (FAc) en el ojo, durante un máximo de 36 meses. Se dedica al desarrollo para el tratamiento del edema macular diabético (EMD). El EMD es una enfermedad de la retina que afecta a las personas con diabetes y puede provocar una grave pérdida de visión y ceguera. ILUVIEN también puede utilizarse para prevenir la recaída en la uveítis no infecciosa recurrente que afecta al segmento posterior del ojo (NIU-PS). La empresa comercializa ILUVIEN directamente en Estados Unidos, Alemania, Reino Unido, Portugal e Irlanda.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com